Recently, ImmuneOnco Biopharma, a partner of Shanghai Medicilon Inc., announced that its newly developed immune checkpoint inhibitor (Project No: IMM01) has been approved by the National Medical Products Administration (NMPA) clinical trial license (Acceptance No: CXSL1900028), which marks the beginning of a new phase of research on the first CD47 fusion protein drug in China.Read more
Press Events
By medicilon | Uncategorized | 4 June, 2019 |
The 2019 BIO International Conference (BIO) will take place in Philadelphia, PA from June 3-6. The BIO attracts 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. Our Directors of BD, Dr. Walter Xie, Dr. Mingzhu Zhang and Sally Tang will attend theRead more
By medicilon | Our Events | 10 January, 2019 |
Medicilon held the Preclincial and IND Declaration Seminar in Chengdu, China. Medicilon CEO Chun-Lin Chen gave a speech during the seminar where he shared his experience on IND filling for both US and China. Professor Shuangqing Peng had a topic on New Drug Safety Evaluation Approach. Dr. Baomin Xin, Medicilon VP of DMPK and BA,Read more
By medicilon | Our Events | 21 December, 2018 |
Dear Clients, Collaborative Partners and Friends, As the end of year is approaching, we would like to express our sincere gratitude for your business. Thank you so much for all your trust and support! During the season, the team at Medicilon wishes you peace, joy and prosperity throughout the coming year. Warmest Holiday Greetings toRead more
